Bernd Rolauffs

Florian Koerber

Knutsen

Mason

Paul

Wolf Rogowski

 Since the first pioneering scientists explored the potential of using human cells for therapeutic purposes the branch of regenerative medicine has evolved to become a mature industry. The focus has switched from ‘what can be done‘ to ‘what can be commercialized‘. Timely health economic evaluation supports successful marketing by establishing the value of a product from a healthcare system perspective. This article reports results from a research project on early health economic evaluation in collaboration with developers, clinicians and manufacturers. We present an approach to determine an early value-based price for a new treatment of cartilage defects of the knee from the area of regenerative medicine. Examples of using evaluation results for the purpose of business planning, market entry, preparing the coverage decision and managed entry are discussed. </jats:p

Early evaluation and value-based pricing of regenerative medicine technologies

Abstract

Similar works

Full text

Available Versions

Crossref